Experimental combo targets stubborn leukemia in tiny trial
NCT ID NCT05441514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of two drugs, enasidenib and cobimetinib, in just 3 patients with a specific form of acute myeloid leukemia (AML) that had come back or didn't respond to treatment. The goal was to see if the combination was safe and to find the best dose. Both drugs work by blocking signals that help cancer cells grow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Enasidenib and cobimetinib
What this could lead to
If it works, this combination could offer a new treatment option for people with a hard-to-treat form of AML that has returned or not responded to other therapies.
What could go wrong
This was a very early, small phase 1 trial with only 3 patients, so results are very preliminary. The combination may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States